1. NAME OF THE MEDICINAL PRODUCT

TRADEMARK 10 mg/10 mg film-coated tablets
TRADEMARK 10 mg/20 mg film-coated tablets
TRADEMARK 10 mg/40 mg film-coated tablets
TRADEMARK 10 mg/80 mg film-coated tablets

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each film-coated tablet contains 10 mg ezetimibe and 10, 20, 40 or 80 mg of atorvastatin (as atorvastatin calcium trihydrate).

Excipients with known effect:
Each 10 mg/10 mg film-coated tablet contains 153 mg of lactose.
Each 10 mg/20 mg film-coated tablet contains 179 mg of lactose.
Each 10 mg/40 mg film-coated tablet contains 230 mg of lactose.
Each 10 mg/80 mg film-coated tablet contains 334 mg of lactose.

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Film-coated tablet

10 mg/10 mg tablet: Capsule-shaped, biconvex, white to off-white, film-coated, size 12.74 mm x 5.10 mm, “257” debossed on one side
10 mg/20 mg tablet: Capsule-shaped, biconvex, white to off-white, film-coated, size 14.48 mm x 5.79 mm, “333” debossed on one side
10 mg/40 mg tablet: Capsule-shaped, biconvex, white to off-white, film-coated size 16.38 mm x 6.27 mm, “337” debossed on one side
10 mg/80 mg tablet: Capsule-shaped, biconvex, white to off-white, film-coated, size 19.05 mm x 7.94 mm, “357” debossed on one side

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

Prevention of Cardiovascular Events
TRADEMARK is indicated to reduce the risk of cardiovascular events (see section 5.1) in patients with coronary heart disease (CHD) and a history of acute coronary syndrome (ACS), either previously treated with a statin or not.

Hypercholesterolaemia
TRADEMARK is indicated as adjunctive therapy to diet for use in adults with primary (heterozygous familial and non-familial) hypercholesterolaemia or mixed hyperlipidaemia where use of a combination product is appropriate

- patients not appropriately controlled with a statin alone
- patients already treated with a statin and ezetimibe

Homozygous Familial Hypercholesterolaemia (HoFH)
TRADEMARK is indicated as adjunctive therapy to diet for use in adults with HoFH. Patients may also receive adjunctive treatments (e.g., low-density lipoprotein [LDL] apheresis).
4.2 Posology and method of administration

Posology

Hypercholesterolaemia and/or Coronary Heart Disease (with ACS History)
The patient should be on an appropriate lipid lowering diet and should continue on this diet during treatment with TRADEMARK.

The dose range of TRADEMARK is 10/10 mg/day through 10/80 mg/day. The typical dose is 10/10 mg once a day. The patient’s low-density lipoprotein cholesterol (LDL-C) level, coronary heart disease risk status, and response to current cholesterol-lowering therapy should be considered when starting therapy or adjusting the dose.

The dose of TRADEMARK should be individualised based on the known efficacy of the various dose strengths of TRADEMARK (see section 5.1, Table 3) and the response to the current cholesterol-lowering therapy. Adjustment of dose should be made at intervals of 4 weeks or more.

Homozygous Familial Hypercholesterolaemia
The dose of TRADEMARK in patients with homozygous FH is 10/10 to 10/80 mg daily.
TRADEMARK may be used as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) in these patients or if such treatments are unavailable.

Coadministration with other medicines
Dosing of TRADEMARK should occur either ≥2 hours before or ≥4 hours after administration of a bile acid sequestrant.

In patients taking hepatitis C antiviral agents containing elbasvir or grazoprevir concomitantly with TRADEMARK, the dose of TRADEMARK should not exceed 10/20 mg/day (see sections 4.4 and 4.5).

Older people
No dose adjustment is required for older patients (see section 5.2).

Paediatric population
The safety and efficacy of TRADEMARK in children has not been established (see section 5.2). No data are available.

Patients with hepatic impairment
TRADEMARK should be used with caution in patients with hepatic impairment (see sections 4.4 and 5.2). TRADEMARK is contraindicated in patients with active liver disease (see section 4.3).

Patients with renal impairment
No dose adjustment is required for renally impaired patients (see section 5.2).

Method of administration
TRADEMARK is for oral administration. TRADEMARK can be administered as a single dose at any time of the day, with or without food.

4.3 Contraindications

Hypersensitivity to the active substances or to any of the excipients listed in section 6.1.

Therapy with TRADEMARK is contraindicated during pregnancy and breast-feeding, and in women of child-bearing potential not using appropriate contraceptive measures (see section 4.6).
TRADEMARK is contraindicated in patients with active liver disease or unexplained persistent elevations in serum transaminases exceeding 3 times the upper limit of normal (ULN).

**4.4 Special warnings and precautions for use**

Myopathy/Rhabdomyolysis
In post-marketing experience with ezetimibe, cases of myopathy and rhabdomyolysis have been reported. Most patients who developed rhabdomyolysis were taking a statin concomitantly with ezetimibe. However, rhabdomyolysis has been reported very rarely with ezetimibe monotherapy and very rarely with the addition of ezetimibe to other agents known to be associated with increased risk of rhabdomyolysis.

TRADEMARK contains atorvastatin. Atorvastatin, like other HMG-CoA reductase inhibitors, may in rare occasions affect the skeletal muscle and cause myalgia, myositis, and myopathy that may progress to rhabdomyolysis, a potentially life-threatening condition characterised by markedly elevated creatine phosphokinase (CPK) levels (>10 times ULN), myoglobinaemia and myoglobinuria, which may lead to renal failure.

**Before the treatment**
TRADEMARK should be prescribed with caution in patients with pre-disposing factors for rhabdomyolysis. A CPK level should be measured before starting treatment in the following situations:
- renal impairment
- hypothyroidism
- personal or familial history of hereditary muscular disorders
- previous history of muscular toxicity with a statin or fibrate
- previous history of liver disease and/or where substantial quantities of alcohol are consumed
- in elderly (age >70 years), the necessity of such measurement should be considered, according to the presence of other predisposing factors for rhabdomyolysis
- situations where an increase in plasma levels may occur, such as interactions (see section 4.5) and special populations including genetic subpopulations (see section 5.2)

In such situations, the risk of treatment should be considered in relation to possible benefit, and clinical monitoring is recommended.

If CPK levels are significantly elevated (>5 times ULN) at baseline, treatment should not be started.

**Creatine phosphokinase measurement**
Creatine phosphokinase (CPK) should not be measured following strenuous exercise or in the presence of any plausible alternative cause of CPK increase as this makes value interpretation difficult. If CPK levels are significantly elevated at baseline (>5 times ULN), levels should be remeasured within 5 to 7 days later to confirm the results.

**Whilst on treatment**
- Patients must be asked to promptly report muscle pain, cramps, or weakness especially if accompanied by malaise or fever or if muscle signs and symptoms persist after discontinuing TRADEMARK.
- If such symptoms occur whilst a patient is receiving treatment with TRADEMARK, their CPK levels should be measured. If these levels are found to be significantly elevated (>5 times ULN), treatment should be stopped.
- If muscular symptoms are severe and cause daily discomfort, even if the CPK levels are elevated to ≤5 times ULN, treatment discontinuation should be considered.
- If symptoms resolve and CPK levels return to normal, then re-introduction of TRADEMARK or introduction of another statin-containing product may be considered at the lowest dose and with close monitoring.
• TRADEMARK must be discontinued if clinically significant elevation of CPK levels (>10 times ULN) occur, or if rhabdomyolysis is diagnosed or suspected.
• There have been very rare reports of an immune-mediated necrotising myopathy (IMNM) during or after treatment with some statins. IMNM is clinically characterised by persistent proximal muscle weakness and elevated serum creatine kinase, which persist despite discontinuation of statin treatment.

Due to the atorvastatin component of TRADEMARK, the risk of rhabdomyolysis is increased when TRADEMARK is administered concomitantly with certain medicinal products that may increase the plasma concentration of atorvastatin such as potent inhibitors of CYP3A4 or transport proteins (e.g. ciclosporin, telithromycin, clarithromycin, delavirdine, stiripentol, ketoconazole, voriconazole, itraconazole, posaconazole, and HIV protease inhibitors including ritonavir, lopinavir, atazanavir, indinavir, darunavir, etc). The risk of myopathy may also be increased with the concomitant use of gemfibrozil and other fibric acid derivatives, erythromycin, niacin, the hepatitis C antiviral agents boceprevir, telaprevir, elbasvir, grazoprevir, or the combination of tipranavir/ritonavir. If possible, alternative (non-interacting) therapies should be considered instead of these medicinal products. (See section 4.8.)

In cases where coadministration of these medicinal products with TRADEMARK is necessary, the benefit and the risk of concurrent treatment should be carefully considered. When patients are receiving medicinal products that increase the plasma concentration of atorvastatin, a lower maximum dose of TRADEMARK is recommended. In addition, in the case of potent CYP3A4 inhibitors, a lower starting dose of TRADEMARK should be considered and appropriate clinical monitoring of these patients is recommended (see section 4.5).

Atorvastatin must not be co-administered with systemic formulations of fusidic acid or within 7 days of stopping fusidic acid treatment. In patients where the use of systemic fusidic acid is considered essential, statin treatment should be discontinued throughout the duration of fusidic acid treatment. There have been reports of rhabdomyolysis (including some fatalities) in patients receiving fusidic acid and statins in combination (see section 4.5). The patient should be advised to seek medical advice immediately if they experience any symptoms of muscle weakness, pain or tenderness.

Statin therapy may be re-introduced seven days after the last dose of fusidic acid.

In exceptional circumstances, where prolonged systemic fusidic acid is needed, e.g., for the treatment of severe infections, the need for co-administration of TRADEMARK and fusidic acid should only be considered on a case by case basis and under close medical supervision.

Liver Enzymes
In controlled coadministration trials in patients receiving ezetimibe and atorvastatin, consecutive transaminase elevations (≥3 times the upper limit of normal [ULN]) have been observed (see section 4.8.).

Liver function tests should be performed before the initiation of treatment and periodically thereafter. Patients who develop any signs or symptoms suggestive of liver injury should have liver function tests performed. Patients who develop increased transaminase levels should be monitored until the abnormality(ies) resolve. Should an increase in transaminases of greater than 3 times the ULN persist, reduction of dose or withdrawal of TRADEMARK is recommended.

TRADEMARK should be used with caution in patients who consume substantial quantities of alcohol and/or have a history of liver disease.

Hepatic Insufficiency
Due to the unknown effects of the increased exposure to ezetimibe in patients with moderate or severe hepatic insufficiency, TRADEMARK is not recommended (see section 5.2).
Fibrates
The safety and efficacy of ezetimibe administered with fibrates have not been established; therefore, coadministration of TRADEMARK and fibrates is not recommended (see section 4.5).

Ciclosporin
Caution should be exercised when initiating TRADEMARK in the setting of ciclosporin. Ciclosporin concentrations should be monitored in patients receiving TRADEMARK and ciclosporin (see section 4.5).

Anticoagulants
If TRADEMARK is added to warfarin, another coumarin anticoagulant, or fluindione, the International Normalised Ratio (INR) should be appropriately monitored (see section 4.5).

Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL)
In a post-hoc analysis of stroke subtypes in patients without coronary heart disease (CHD) who had a recent stroke or transient ischemic attack (TIA) there was a higher incidence of hemorrhagic stroke in patients initiated on atorvastatin 80 mg compared to placebo. The increased risk was particularly noted in patients with prior hemorrhagic stroke or lacunar infarct at study entry. For patients with prior hemorrhagic stroke or lacunar infarct, the balance of risks and benefits of atorvastatin 80 mg is uncertain, and the potential risk of hemorrhagic stroke should be carefully considered before initiating treatment (see section 5.1).

Interstitial lung disease
Exceptional cases of interstitial lung disease have been reported with some statins, especially with long term therapy (see section 4.8). Presenting features can include dyspnoea, non-productive cough and deterioration in general health (fatigue, weight loss and fever). If it is suspected a patient has developed interstitial lung disease, statin therapy should be discontinued.

Diabetes mellitus
Some evidence suggests that statins as a class raise blood glucose and in some patients, at high risk of future diabetes, may produce a level of hyperglycaemia where formal diabetes care is appropriate. This risk, however, is outweighed by the reduction in vascular risk with statins and therefore should not be a reason for stopping statin treatment. Patients at risk (fasting glucose 5.6 to 6.9 mmol/L, BMI>30kg/m2, raised triglycerides, hypertension) should be monitored both clinically and biochemically according to national guidelines.

Excipients
TRADEMARK contains lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency, or glucose-galactose malabsorption should not take this medicine.

4.5 Interaction with other medicinal products and other forms of interaction

Pharmacodynamic interactions
Atorvastatin, a component of TRADEMARK, is metabolized by cytochrome P450 3A4 (CYP3A4) and is a substrate to transport proteins e.g. the hepatic uptake transporter OATP1B1. Concomitant administration of medicinal products that are inhibitors of CYP3A4 or transport proteins may lead to increased plasma concentrations of atorvastatin and an increased risk of myopathy. The risk might also be increased at concomitant administration of TRADEMARK with other medicinal products that have a potential to induce myopathy, such as fibric acid derivatives and ezetimibe (see section 4.4).

Pharmacokinetic interactions
TRADEMARK
No clinically significant pharmacokinetic interaction was seen when ezetimibe was coadministered with atorvastatin.

Effects of other medicinal products on TRADEMARK
Ezetimibe

**Antacids**: Concomitant antacid administration decreased the rate of absorption of ezetimibe but had no effect on the bioavailability of ezetimibe. This decreased rate of absorption is not considered clinically significant.

**Cholestyramine**: Concomitant cholestyramine administration decreased the mean area under the curve (AUC) of total ezetimibe (ezetimibe + ezetimibe glucuronide) approximately 55%. The incremental low-density lipoprotein cholesterol (LDL-C) reduction due to adding TRADEMARK to cholestyramine may be lessened by this interaction (see section 4.2).

**Cyclosporin**: In a study of eight post-renal transplant patients with creatinine clearance of >50 mL/min on a stable dose of ciclosporin, a single 10-mg dose of ezetimibe resulted in a 3.4-fold (range 2.3- to 7.9-fold) increase in the mean AUC for total ezetimibe compared to a healthy control population, receiving ezetimibe alone, from another study (n=17). In a different study, a renal transplant patient with severe renal insufficiency who was receiving ciclosporin and multiple other medicinal products demonstrated a 12-fold greater exposure to total ezetimibe compared to concurrent controls receiving ezetimibe alone. In a two-period crossover study in twelve healthy subjects, daily administration of 20 mg ezetimibe for 8 days with a single 100-mg dose of ciclosporin on Day 7 resulted in a mean 15% increase in ciclosporin AUC (range 10% decrease to 51% increase) compared to a single 100-mg dose of ciclosporin alone. A controlled study on the effect of coadministered ezetimibe on ciclosporin exposure in renal transplant patients has not been conducted. Caution should be exercised when initiating TRADEMARK in the setting of ciclosporin. Ciclosporin concentrations should be monitored in patients receiving TRADEMARK and ciclosporin (see section 4.4).

**Fibrates**: Concomitant fenofibrate or gemfibrozil administration increased total ezetimibe concentrations approximately 1.5- and 1.7-fold, respectively. Although these increases are not considered clinically significant, coadministration of TRADEMARK with fibrates is not recommended (see section 4.4).

**Atorvastatin**

**CYP3A4 inhibitors**: Potent CYP3A4 inhibitors have been shown to lead to markedly increased concentrations of atorvastatin (see Table 1 and specific information below). Coadministration of potent CYP3A4 inhibitors (e.g. ciclosporin, telithromycin, clarithromycin, delavirdine, strипентол, ketoconazole, voriconazole, itraconazole, posaconazole and HIV protease inhibitors including ritonavir, lopinavir, atazanavir, indinavir, darunavir, etc.) should be avoided if possible. In cases where coadministration of these medicinal products with TRADEMARK cannot be avoided, lower starting and maximum doses of TRADEMARK should be considered and appropriate clinical monitoring of the patient is recommended (see Table 1).

Moderate CYP3A4 inhibitors (e.g. erythromycin, diltiazem, verapamil and fluconazole) may increase plasma concentrations of atorvastatin (see Table 1). An increased risk of myopathy has been observed with the use of erythromycin in combination with statins. Interaction studies evaluating the effects of amiodarone or verapamil on atorvastatin have not been conducted. Both amiodarone and verapamil are known to inhibit CYP3A4 activity and coadministration with TRADEMARK may result in increased exposure to atorvastatin. Therefore, a lower maximum dose of TRADEMARK should be considered and appropriate clinical monitoring of the patient is recommended when concomitantly used with moderate CYP3A4 inhibitors. Appropriate clinical monitoring is recommended after initiation or following dose adjustments of the inhibitor.

**Inhibitors of Breast Cancer Resistant Protein (BCRP)**: Concomitant administration of products that are inhibitors of BCRP (e.g., elbasvir and grazoprevir) may lead to increased plasma concentrations of atorvastatin and an increased risk of myopathy; therefore a dose adjustment of atorvastatin should be considered depending on the prescribed dose. Co-administration of elbasvir and grazoprevir with atorvastatin increases plasma concentrations of atorvastatin 1.9-fold (see Table 1); therefore, the dose
of TRADEMARK should not exceed 10/20 mg daily in patients receiving concomitant medications with products containing elbasvir or grazoprevir (see section 4.2 and 4.4).

**Inducers of cytochrome P450 3A4:** Concomitant administration of atorvastatin with inducers of cytochrome P450 3A4 (e.g., efavirenz, rifampicin, St. John’s Wort) can lead to variable reductions in plasma concentrations of atorvastatin. Due to the dual interaction mechanism of rifampicin, (cytochrome P450 3A4 induction and inhibition of hepatocyte uptake transporter OATP1B1), simultaneous coadministration of TRADEMARK with rifampicin is recommended, as delayed administration of atorvastatin after administration of rifampicin has been associated with a significant reduction in atorvastatin plasma concentrations. The effect of rifampicin on atorvastatin concentrations in hepatocytes is, however, unknown and if concomitant administration cannot be avoided, patients should be carefully monitored for efficacy.

**Transport protein inhibitors:** Inhibitors of transport proteins (e.g. ciclosporin) can increase the systemic exposure of atorvastatin (see Table 1). The effect of inhibition of hepatic uptake transporters on atorvastatin concentrations in hepatocytes is unknown. If concomitant administration cannot be avoided, a dose reduction of TRADEMARK and clinical monitoring for efficacy is recommended (see Table 1).

**Gemfibrozil/fibric acid derivatives:** The use of fibrates alone is occasionally associated with muscle-related events, including rhabdomyolysis. The risk of these events may be increased with the concomitant use of fibric acid derivatives and atorvastatin.

**Ezetimibe:** The use of ezetimibe alone is associated with muscle-related events, including rhabdomyolysis. The risk of these events may therefore be increased with concomitant use of ezetimibe and atorvastatin. Appropriate clinical monitoring of these patients is recommended.

**Colestipol:** Plasma concentrations of atorvastatin and its active metabolites were lower (by approx. 25%) when colestipol was coadministered with atorvastatin. However, lipid effects were greater when atorvastatin and colestipol were coadministered than when either medicinal product was given alone.

**Fusidic acid:** The risk of myopathy including rhabdomyolysis may be increased by the concomitant administration of systemic fusidic acid with statins. The mechanism of this interaction (whether it is pharmacodynamic or pharmacokinetic, or both) is yet unknown. There have been reports of rhabdomyolysis (including some fatalities) in patients receiving this combination. If treatment with systemic fusidic acid is necessary, atorvastatin treatment should be discontinued throughout the duration of the fusidic acid treatment. Also see section 4.4

**Colchicine:** Although interaction studies with atorvastatin and colchicine have not been conducted, cases of myopathy have been reported with atorvastatin co-administered with colchicine, and caution should be exercised when prescribing atorvastatin with colchicine.

**Boceprevir:** Exposure to atorvastatin was increased when administered with boceprevir. When coadministration with TRADEMARK is required, starting with the lowest possible dose of TRADEMARK should be considered with titration up to desired clinical effect while monitoring for safety, without exceeding a daily dose of 10/20 mg. For patients currently taking TRADEMARK, the dose of TRADEMARK should not exceed a daily dose of 10/20 mg during coadministration with boceprevir.

**Effects of TRADEMARK on the pharmacokinetics of other medicinal products**

**Ezetimibe**

In preclinical studies, it has been shown that ezetimibe does not induce cytochrome P450 drug metabolising enzymes. No clinically significant pharmacokinetic interactions have been observed
between ezetimibe and drugs known to be metabolised by cytochromes P450 1A2, 2D6, 2C8, 2C9, and 3A4, or N-acetyltransferase.

**Anticoagulants:** Concomitant administration of ezetimibe (10 mg once daily) had no significant effect on bioavailability of warfarin and prothrombin time in a study of twelve healthy adult males. However, there have been post-marketing reports of increased International Normalised Ratio (INR) in patients who had ezetimibe added to warfarin or fluindione. If TRADEMARK is added to warfarin, another coumarin anticoagulant, or fluindione, INR should be appropriately monitored (see section 4.4).

**Atorvastatin**

**Digoxin:** When multiple doses of digoxin and 10 mg atorvastatin were coadministered, steady-state digoxin concentrations increased slightly. Patients taking digoxin should be monitored appropriately.

**Oral contraceptives:** Coadministration of atorvastatin with an oral contraceptive produced increases in plasma concentrations of norethisterone and ethinyl estradiol.

**Warfarin:** In a clinical study in patients receiving chronic warfarin therapy, coadministration of atorvastatin 80 mg daily with warfarin caused a small decrease of about 1.7 seconds in prothrombin time during the first 4 days of dosing, which returned to normal within 15 days of atorvastatin treatment. Although only very rare cases of clinically significant anticoagulant interactions have been reported, prothrombin time should be determined before starting TRADEMARK in patients taking coumarin anticoagulants and frequently enough during early therapy to ensure that no significant alteration of prothrombin time occurs. Once a stable prothrombin time has been documented, prothrombin times can be monitored at the intervals usually recommended for patients on coumarin anticoagulants. If the dose of TRADEMARK is changed or discontinued, the same procedure should be repeated. Atorvastatin therapy has not been associated with bleeding or with changes in prothrombin time in patients not taking anticoagulants.

### Table 1
Effect of Coadministered Medicinal Products on the Pharmacokinetics of Atorvastatin

<table>
<thead>
<tr>
<th>Coadministered Medicinal Product and Dosing Regimen</th>
<th>Atorvastatin</th>
<th>TRADEMARK</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Dose (mg)</td>
<td>Change in AUC&lt;sup&gt;↑&lt;/sup&gt;</td>
</tr>
<tr>
<td>Tipranavir 500 mg BID/ Ritonavir 200 mg BID, 8 days (Days 14 to 21)</td>
<td>40 mg on Day 1, 10 mg on Day 20</td>
<td>↑ 9.4 fold</td>
</tr>
<tr>
<td>Ciclosporin 5.2 mg/kg/day, stable dose</td>
<td>10 mg OD for 28 days</td>
<td>↑ 8.7 fold</td>
</tr>
<tr>
<td>Lopinavir 400 mg BID/ Ritonavir 100 mg BID, 14 days</td>
<td>20 mg OD for 4 days</td>
<td>↑ 5.9 fold</td>
</tr>
<tr>
<td>Drug</td>
<td>Dosage and Schedule</td>
<td>Change</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>-----------------------------------------------</td>
<td>--------</td>
</tr>
<tr>
<td>Clarithromycin 500 mg BID, 9 days</td>
<td>80 mg OD for 8 days</td>
<td>↑ 4.4 fold</td>
</tr>
<tr>
<td>Saquinavir 400 mg BID/Ritonavir 300 mg BID from Days 5-7, increased to 400 mg BID on Day 8), Days 5-18, 30 min after atorvastatin dosing</td>
<td>40 mg OD for 4 days</td>
<td>↑ 3.9 fold</td>
</tr>
<tr>
<td>Darunavir 300 mg BID/ Ritonavir 100 mg BID, 9 days</td>
<td>10 mg OD for 4 days</td>
<td>↑ 3.3 fold</td>
</tr>
<tr>
<td>Itraconazole 200 mg OD, 4 days</td>
<td>40 mg SD</td>
<td>↑ 3.3 fold</td>
</tr>
<tr>
<td>Fosamprenavir 700 mg BID/ Ritonavir 100 mg BID, 14 days</td>
<td>10 mg OD for 4 days</td>
<td>↑ 2.5 fold</td>
</tr>
<tr>
<td>Fosamprenavir 1400 mg BID, 14 days</td>
<td>10 mg OD for 4 days</td>
<td>↑ 2.3 fold</td>
</tr>
<tr>
<td>Nelfinavir 1250 mg BID, 14 days</td>
<td>10 mg OD for 28 days</td>
<td>↑ 1.7 fold</td>
</tr>
<tr>
<td>Grapefruit Juice, 240 mL OD*</td>
<td>40 mg SD</td>
<td>↑ 37%</td>
</tr>
<tr>
<td>Diltiazem 240 mg OD, 28 days</td>
<td>40 mg SD</td>
<td>↑ 51%</td>
</tr>
<tr>
<td>Erythromycin 500 mg QID, 7 days</td>
<td>10 mg SD</td>
<td>↑ 33%^</td>
</tr>
<tr>
<td>Amlodipine 10 mg, single dose</td>
<td>80 mg SD</td>
<td>↑ 18%</td>
</tr>
<tr>
<td>Cimetidine 300 mg QID, 2 weeks</td>
<td>10 mg OD for 4 weeks</td>
<td>↓ less than 1%^</td>
</tr>
<tr>
<td>Antacid suspension of magnesium and aluminium hydroxides, 30 mL QID, 2 weeks</td>
<td>10 mg OD for 4 weeks</td>
<td>↓ 35%^</td>
</tr>
<tr>
<td>Efavirenz 600 mg OD, 14 days</td>
<td>10 mg for 3 days</td>
<td>↓ 41%</td>
</tr>
<tr>
<td>Rifampicin 600 mg OD, 7 days (coadministered)</td>
<td>40 mg SD</td>
<td>↑ 30%</td>
</tr>
</tbody>
</table>
Rifampicin  600 mg OD, 5 days (doses separated)  | 40 mg SD  | ↓ 80%  | rifampicin is recommended, with clinical monitoring.

Gemfibrozil  600 mg BID, 7 days  | 40 mg SD  | ↑ 35%  | Not recommended.

Fenofibrate 160 mg OD, 7 days  | 40 mg SD  | ↑ 3%  | Not recommended.

Boceprevir 800 mg TID, 7 days  | 40 mg SD  | ↑ 2.3 fold  | Lower starting dose and clinical monitoring of these patients is recommended. The dose of TRADEMARK should not exceed a daily dose of 10/20 mg during coadministration with boceprevir.

Elbasvir 50 mg + Grazoprevir 200 mg QD, 13 days  | 20 mg, SD  | ↑ 1.9 fold  | The dose of TRADEMARK should not exceed a daily dose of 10/20 mg during coadministration with products containing elbasvir or grazoprevir.

* Data given as x-fold change represent a simple ratio between co-administration and atorvastatin alone (i.e., 1-fold = no change). Data given as % change represent % difference relative to atorvastatin alone (i.e., 0% = no change).

# See sections 4.4 and 4.5 for clinical significance.

* Contains one or more components that inhibit CYP3A4 and can increase plasma concentrations of medicinal products metabolized by CYP3A4. Intake of one 240 ml glass of grapefruit juice also resulted in a decreased AUC of 20.4% for the active orthohydroxy metabolite. Large quantities of grapefruit juice (over 1.2 l daily for 5 days) increased AUC of atorvastatin 2.5 fold and AUC of active (atorvastatin and metabolites).

^ Total atorvastatin equivalent activity
Increase is indicated as “↑”, decrease as “↓”
OD = once daily; SD = single dose; BID = twice daily; TID = three times daily; QID = four times daily

Table 2
Effect of Atorvastatin on the Pharmacokinetics of Coadministered Medicinal Products

<table>
<thead>
<tr>
<th>Atorvastatin and Dosing Regimen</th>
<th>Coadministered Medicinal Product/Dose (mg)</th>
<th>Medicinal Product Change in AUC*</th>
<th>TRADEMARK Clinical Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>80 mg OD for 10 days</td>
<td>Digoxin 0.25 mg OD, 20 days</td>
<td>↑ 15%</td>
<td>Patients taking digoxin should be monitored appropriately.</td>
</tr>
<tr>
<td>40 mg OD for 22 days</td>
<td>Oral contraceptive OD, 2 months</td>
<td>↑ 28%</td>
<td>No specific recommendation.</td>
</tr>
<tr>
<td></td>
<td>-norethisterone 1 mg</td>
<td>↑ 19%</td>
<td></td>
</tr>
<tr>
<td></td>
<td>-ethinyl estradiol 35 μg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>80 mg OD for 15 days</td>
<td>*Phenazone, 600 mg SD</td>
<td>↑ 3%</td>
<td>No specific recommendation</td>
</tr>
<tr>
<td>10 mg, OD for 4 days</td>
<td>Fosamprenavir 1400 mg BID, 14 days</td>
<td>↓ 27%</td>
<td>No specific recommendation</td>
</tr>
</tbody>
</table>

* Data given as % change represent % difference relative to atorvastatin alone (i.e., 0% = no change)
* Co-administration of multiple doses of atorvastatin and phenazone showed little or no detectable effect in the clearance of phenazone.

Increase is indicated as “↑”, decrease as “↓”
OD = once daily; SD = single dose; BID = twice daily

4.6 Fertility, pregnancy and lactation

**Women of childbearing potential**
Women of childbearing potential should use appropriate contraceptive measures during treatment (see section 4.3).

**Pregnancy**
Atherosclerosis is a chronic process, and ordinarily discontinuation of lipid-lowering drugs during pregnancy should have little impact on the long-term risk associated with primary hypercholesterolaemia.

**TRADEMARK**
TRADEMARK is contraindicated during pregnancy (see section 4.3). No clinical data are available on the use of TRADEMARK during pregnancy.

The coadministration of ezetimibe and atorvastatin in pregnant rats indicated that there was a test article-related increase in the skeletal variation “reduced ossification of the sternebrae” in the high dose ezetimibe/atorvastatin group. This may be related to the observed decrease in foetal body weights. In pregnant rabbits a low incidence of skeletal deformities (fused sternebrae, fused caudal vertebrae and asymmetrical sternebra variation) were observed.

**Atorvastatin**
Safety in pregnant women has not been established. No controlled clinical trials with atorvastatin have been conducted in pregnant women. Rare reports of congenital anomalies following intrauterine exposure to HMG-CoA reductase inhibitors have been received. Animal studies have shown toxicity to reproduction (see section 5.3).

**Ezetimibe**
No clinical data are available on the use of ezetimibe during pregnancy.

**Breast-feeding**
TRADEMARK is contraindicated during breast-feeding. Because of the potential for serious adverse reactions, women taking TRADEMARK should not breast-feed their infants. Studies on rats have shown that ezetimibe is secreted into breast milk. In rats, plasma concentrations of atorvastatin and its active metabolites are similar to those in milk. It is not known if the active components of TRADEMARK are secreted into human breast milk. (See section 4.3.)

**Fertility**
No fertility studies were conducted with TRADEMARK.

**Atorvastatin**
In animal studies atorvastatin had no effect on male or female fertility.

**Ezetimibe**
Ezetimibe had no effect on the fertility of male or female rats.
4.7 Effects on ability to drive and use machines

TRADEMARK has negligible influence on the ability to drive and use machines. However, when driving vehicles or operating machines, it should be taken into account that dizziness has been reported.

4.8 Undesirable effects

Summary of the safety profile
TRADEMARK (or coadministration of ezetimibe and atorvastatin equivalent to TRADEMARK) has been evaluated for safety in more than 2400 patients in 7 clinical trials.

Tabulated list of adverse reactions

Frequencies are defined as: very common (≥1/10); common ≥1/100, <1/10); uncommon (≥1/1000, <1/100); rare (≥1/10,000, <1/1000); and very rare (<1/10,000).

<table>
<thead>
<tr>
<th>System organ class</th>
<th>Adverse reaction</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infections and Infestations</td>
<td>influenza</td>
<td>Uncommon</td>
</tr>
<tr>
<td>Psychiatric disorders</td>
<td>depression; insomnia; sleep disorder</td>
<td>Uncommon</td>
</tr>
<tr>
<td>Nervous system disorders</td>
<td>dizziness; dysgeusia; headache; paraesthesia</td>
<td>Uncommon</td>
</tr>
<tr>
<td>Cardiac disorders</td>
<td>sinus bradycardia</td>
<td>Uncommon</td>
</tr>
<tr>
<td>Vascular disorders:</td>
<td>hot flush</td>
<td>Uncommon</td>
</tr>
<tr>
<td>Respiratory, thoracic and mediastinal disorders</td>
<td>dyspnea</td>
<td>Uncommon</td>
</tr>
<tr>
<td>Gastrointestinal disorders</td>
<td>diarrhoea; abdominal discomfort; abdominal distension; abdominal pain; abdominal pain lower; abdominal pain upper; constipation; dyspepsia; flatulence; frequent bowel movements; gastritis; nausea; stomach discomfort</td>
<td>Uncommon</td>
</tr>
<tr>
<td>Skin and subcutaneous tissue disorders</td>
<td>acne; urticaria</td>
<td>Uncommon</td>
</tr>
<tr>
<td>Musculoskeletal and connective tissue disorders</td>
<td>myalgia; arthralgia; back pain; muscle fatigue; muscle spasms; muscular weakness; pain in extremity</td>
<td>Uncommon</td>
</tr>
<tr>
<td>General disorders and administration site conditions:</td>
<td>asthenia; fatigue; malaise; edema</td>
<td>Uncommon</td>
</tr>
<tr>
<td>Investigations:</td>
<td>ALT and/or AST increased; alkaline phosphatase increased; blood creatine phosphokinase (CPK) increased; gamma-glutamyltransferase increased; hepatic enzyme increased; liver function test abnormal; weight increased</td>
<td>Uncommon</td>
</tr>
</tbody>
</table>

Laboratory Values
In controlled clinical trials, the incidence of clinically important elevations in serum transaminases (ALT and/or AST ≥3 X ULN, consecutive) was 0.6% for patients treated with TRADEMARK. These elevations were generally asymptomatic, not associated with cholestasis, and returned to baseline spontaneously or after discontinuation of therapy. (See section 4.4.)

Post-marketing Experience and Other Clinical Trial Experience
The following additional adverse reactions have been reported in post-marketing use with TRADEMARK or in clinical studies or post-marketing use with ezetimibe or atorvastatin:
**Infections and infestations:** nasopharyngitis

**Blood and lymphatic system disorders:** thrombocytopenia

**Immune system disorders:** hypersensitivity, including anaphylaxis, angioedema, rash, and urticaria

**Metabolism and nutrition disorders:** decreased appetite; anorexia; hyperglycaemia; hypoglycaemia

**Psychiatric disorders:** nightmares

**Nervous system disorders:** hypoesthesia; amnesia; peripheral neuropathy

**Eye disorders:** vision blurred; visual disturbance

**Ear and labyrinth disorders:** tinnitus; hearing loss

**Vascular Disorders:** hypertension

**Respiratory, Thoracic and Mediastinal Disorders:** cough; pharyngolaryngeal pain; epistaxis

**Gastrointestinal disorders:** pancreatitis; gastro-oesophageal reflux disease; eructation; vomiting; dry mouth

**Hepatobiliary disorders:** hepatitis; cholelithiasis; cholecystitis; cholestasis; fatal and non-fatal hepatic failure

**Skin and subcutaneous tissue disorders:** alopecia; skin rash; pruritus; erythema multiforme; angioneurotic oedema; dermatitis bullous including erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis

**Musculoskeletal and connective tissue disorders:** myopathy/rhabdomyolysis; neck pain; joint swelling; myositis; immune-mediated necrotizing myopathy (frequency not known) (see section 4.4)

**Reproductive system and breast disorders:** gynecomastia

**General disorders and administration site conditions:** chest pain; pain; peripheral oedema; pyrexia

**Investigations:** white blood cells urine positive

**Injury, poisoning and procedural complications:** tendinopathy, sometimes complicated by rupture

The following adverse events have been reported with some statins:

- sexual dysfunction
- exceptional cases of interstitial lung disease, especially with long term therapy (see section 4.4)
- diabetes mellitus: frequency will depend on the presence or absence of risk factors (fasting blood glucose $\geq5.6$ mmol/L, BMI$>30$kg/m2, raised triglycerides, history of hypertension)

**Reporting of suspected adverse reactions**

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.

4.9 Overdose
TRADEMARK
In the event of an overdose, symptomatic and supportive measures should be employed. Liver function tests should be performed and serum CPK levels should be monitored.

Ezetimibe
In clinical studies, administration of ezetimibe, 50 mg/day to 15 healthy subjects for up to 14 days, or 40 mg/day to 18 patients with primary hyperlipidemia for up to 56 days, was generally well tolerated. A few cases of overdose have been reported; most have not been associated with adverse experiences. Reported adverse experiences have not been serious. In animals, no toxicity was observed after single oral doses of 5000 mg/kg of ezetimibe in rats and mice and 3000 mg/kg in dogs.

Atorvastatin
Due to extensive atorvastatin binding to plasma proteins, haemodialysis is not expected to significantly enhance atorvastatin clearance.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic effects

Pharmacotherapeutic group: Lipid modifying agents, HMG-CoA reductase inhibitors in combination with other lipid modifying agents, ATC code: C10BA05

TRADEMARK (ezetimibe/atorvastatin) is a lipid-lowering product that selectively inhibits the intestinal absorption of cholesterol and related plant sterols and inhibits the endogenous synthesis of cholesterol.

Mechanism of action

TRADEMARK
Plasma cholesterol is derived from intestinal absorption and endogenous synthesis. TRADEMARK contains ezetimibe and atorvastatin, two lipid-lowering compounds with complementary mechanisms of action. TRADEMARK reduces elevated total cholesterol (total-C), LDL-C, apolipoprotein B (Apo B), triglycerides (TG), and non-high-density lipoprotein cholesterol (non-HDL-C), and increases high-density lipoprotein cholesterol (HDL-C) through dual inhibition of cholesterol absorption and synthesis.

Ezetimibe
Ezetimibe inhibits the intestinal absorption of cholesterol. Ezetimibe is orally active and has a mechanism of action that differs from other classes of cholesterol-reducing compounds (e.g., statins, bile acid sequestrants [resins], fibric acid derivatives, and plant stanols). The molecular target of ezetimibe is the sterol transporter, Niemann-Pick C1-Like 1 (NPC1L1), which is responsible for the intestinal uptake of cholesterol and phytosterols.

Ezetimibe localises at the brush border of the small intestine and inhibits the absorption of cholesterol, leading to a decrease in the delivery of intestinal cholesterol to the liver; statins reduce cholesterol synthesis in the liver and together these distinct mechanisms provide complementary cholesterol reduction. In a 2-week clinical study in 18 hypercholesterolaemic patients, ezetimibe inhibited intestinal cholesterol absorption by 54%, compared with placebo.

A series of preclinical studies was performed to determine the selectivity of ezetimibe for inhibiting cholesterol absorption. Ezetimibe inhibited the absorption of [14C]-cholesterol with no effect on the absorption of triglycerides, fatty acids, bile acids, progesterone, ethinyl estradiol, or fat soluble vitamins A and D.

Atorvastatin
Atorvastatin is a selective, competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme responsible for the conversion of 3-hydroxy-3-methyl-glutaryl-coenzyme A to mevalonate, a precursor
of sterols, including cholesterol. Triglycerides and cholesterol in the liver are incorporated into very low-density lipoproteins (VLDL) and released into the plasma for delivery to peripheral tissues. Low-density lipoprotein (LDL) is formed from VLDL and is catabolized primarily through the receptor with high affinity to LDL (LDL receptor).

**Atorvastatin** lowers plasma cholesterol and lipoprotein serum concentrations by inhibiting HMG-CoA reductase and subsequently cholesterol biosynthesis in the liver and increases the number of hepatic LDL receptors on the cell surface for enhanced uptake and catabolism of LDL.

Atorvastatin reduces LDL production and the number of LDL particles. Atorvastatin produces a profound and sustained increase in LDL receptor activity coupled with a beneficial change in the quality of circulating LDL particles. Atorvastatin is effective in reducing LDL-C in patients with homozygous familial hypercholesterolaemia, a population that has not usually responded to lipid-lowering medicinal products.

Atorvastatin has been shown to reduce concentrations of total-C (30% - 46%), LDL-C (41% - 61%), apolipoprotein B (34% - 50%), and triglycerides (14% - 33%) while producing variable increases in HDL-C and apolipoprotein A1 in a dose response study. These results are consistent in patients with heterozygous familial hypercholesterolaemia, nonfamilial forms of hypercholesterolaemia, and mixed hyperlipidaemia, including patients with noninsulin-dependent diabetes mellitus.

**Clinical efficacy and safety**

In controlled clinical studies, **TRADEMARK** significantly reduced total-C, LDL-C, Apo B, and TG, and increased HDL-C in patients with hypercholesterolaemia.

**Primary Hypercholesterolaemia**

In a placebo-controlled study, 628 patients with hyperlipidaemia were randomised to receive placebo, ezetimibe (10 mg), atorvastatin (10 mg, 20 mg, 40 mg, or 80 mg), or coadministered ezetimibe and atorvastatin equivalent to **TRADEMARK** (10/10, 10/20, 10/40, and 10/80) for up to 12-weeks.

Patients receiving all doses of **TRADEMARK** were compared to those receiving all doses of atorvastatin. **TRADEMARK** lowered total-C, LDL-C, Apo B, TG, and non-HDL-C, and increased HDL-C significantly more than atorvastatin alone. (See Table 3.)
### Table 3
Response to TRADEMARK in Patients with Primary Hyperlipidaemia (Mean % Change from Untreated Baseline at 12 weeks)

<table>
<thead>
<tr>
<th>Treatment (Daily Dose)</th>
<th>N</th>
<th>Total-C</th>
<th>LDL-C</th>
<th>Apo B</th>
<th>TG(^a)</th>
<th>HDL-C</th>
<th>Non-HDL-C</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pooled data (All TRADEMARK doses)(^c)</td>
<td>255</td>
<td>-41</td>
<td>-56</td>
<td>-45</td>
<td>-33</td>
<td>+7</td>
<td>-52</td>
</tr>
<tr>
<td>Pooled data (All atorvastatin doses)(^c)</td>
<td>248</td>
<td>-32</td>
<td>-44</td>
<td>-36</td>
<td>-24</td>
<td>+4</td>
<td>-41</td>
</tr>
<tr>
<td>Ezetimibe 10 mg</td>
<td>65</td>
<td>-14</td>
<td>-20</td>
<td>-15</td>
<td>-5</td>
<td>+4</td>
<td>-18</td>
</tr>
<tr>
<td>Placebo</td>
<td>60</td>
<td>+4</td>
<td>+4</td>
<td>+3</td>
<td>-6</td>
<td>+4</td>
<td>+4</td>
</tr>
<tr>
<td>TRADEMARK by dose</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10/10</td>
<td>65</td>
<td>-38</td>
<td>-53</td>
<td>-43</td>
<td>-31</td>
<td>+9</td>
<td>-49</td>
</tr>
<tr>
<td>10/20</td>
<td>62</td>
<td>-39</td>
<td>-54</td>
<td>-44</td>
<td>-30</td>
<td>+9</td>
<td>-50</td>
</tr>
<tr>
<td>10/40</td>
<td>65</td>
<td>-42</td>
<td>-56</td>
<td>-45</td>
<td>-34</td>
<td>+5</td>
<td>-52</td>
</tr>
<tr>
<td>10/80</td>
<td>63</td>
<td>-46</td>
<td>-61</td>
<td>-50</td>
<td>-40</td>
<td>+7</td>
<td>-58</td>
</tr>
<tr>
<td>Atorvastatin by dose</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10 mg</td>
<td>60</td>
<td>-26</td>
<td>-37</td>
<td>-28</td>
<td>-21</td>
<td>+6</td>
<td>-34</td>
</tr>
<tr>
<td>20 mg</td>
<td>60</td>
<td>-30</td>
<td>-42</td>
<td>-34</td>
<td>-23</td>
<td>+4</td>
<td>-39</td>
</tr>
<tr>
<td>40 mg</td>
<td>66</td>
<td>-32</td>
<td>-45</td>
<td>-37</td>
<td>-24</td>
<td>+4</td>
<td>-41</td>
</tr>
<tr>
<td>80 mg</td>
<td>62</td>
<td>-40</td>
<td>-54</td>
<td>-46</td>
<td>-31</td>
<td>+3</td>
<td>-51</td>
</tr>
</tbody>
</table>

\(^a\) For triglycerides, median % change from baseline
\(^b\) Baseline - on no lipid-lowering medicinal product
\(^c\) TRADEMARK pooled (10/10-10/80 mg) significantly reduced total-C, LDL-C, Apo B, TG, non-HDL-C, and significantly increased HDL-C compared to all doses of atorvastatin pooled (10-80 mg).

In a controlled study, the Titration of Atorvastatin Versus Ezetimibe Add-On to Atorvastatin in Patients with Hypercholesterolaemia (TEMPO) study, 184 patients, with an LDL-C level ≥2.6 mmol/L and ≤4.1 mmol/L and at moderate high risk for CHD, received atorvastatin 20 mg for a minimum of 4 weeks prior to randomisation. Patients not at an LDL-C level <2.6 mmol/L were randomised to receive either coadministered ezetimibe and atorvastatin (equivalent to TRADEMARK 10/20) or atorvastatin 40 mg for 6 weeks.

TRADEMARK 10/20 was significantly more effective than doubling the dose of atorvastatin to 40 mg in further reducing total-C (−20% vs. −7%), LDL-C (−31% vs. −11%), Apo B (−21% vs. −8%), and non-HDL-C (−27% vs. −10%). Results for HDL-C and TG between the two treatment groups were not significantly different. Also, significantly more patients receiving TRADEMARK 10/20 attained LDL-C <2.6 mmol/L compared to those receiving atorvastatin 40 mg, 84% vs. 49%.

In a controlled study, The Ezetimibe Plus Atorvastatin Versus Atorvastatin Titration in Achieving Lower LDL-C Targets in Hypercholesterolaemic Patients (EZ-PATH) study, 556 high-cardiovascular-risk patients with a LDL-C level ≥1.8 mmol/L and ≤4.1 mmol/L received atorvastatin 40 mg for a minimum of 4 weeks prior to randomisation. Patients not at a LDL-C level <1.8 mmol/L were randomised to receive either coadministered ezetimibe and atorvastatin (equivalent to TRADEMARK 10/40) or atorvastatin 80 mg for 6 weeks.

TRADEMARK 10/40 was significantly more effective than doubling the dose of atorvastatin to 80 mg in further reducing total-C (−17% vs. −7%), LDL-C (−27% vs. −11%), Apo B (−18% vs. −8%), TG (−12% vs. −6%), and non-HDL-C (−23% vs. −9%). Results for HDL-C between the two treatment groups were not significantly different. Also, significantly more patients receiving TRADEMARK 10/40 attained LDL-C <1.8 mmol/L compared to those receiving atorvastatin 80 mg, 74% vs. 32%.
In a placebo-controlled, 8-week study, 308 hypercholesterolemic patients receiving atorvastatin and not at National Cholesterol Education Program (NCEP) LDL-C goal (LDL-C goal based upon baseline LDL-C and CHD risk status) were randomised to receive either ezetimibe 10 mg or placebo in addition to their on-going atorvastatin therapy.

Among patients not at LDL-C goal at baseline (~83%), significantly more patients receiving ezetimibe coadministered with atorvastatin achieved their LDL-C goal compared to patients receiving placebo coadministered with atorvastatin, 67% vs. 19%. Ezetimibe added to atorvastatin therapy lowered LDL-C significantly more than placebo added to atorvastatin therapy, 25% vs. 4%. Ezetimibe added to atorvastatin therapy also significantly decreased total-C, Apo B, and TG compared with placebo added to atorvastatin therapy.

In a controlled, 12-week, 2-phase study, 1539 high-cardiovascular-risk patients, with a LDL-C level between 2.6 and 4.1 mmol/L, on atorvastatin 10 mg daily were randomized to receive: atorvastatin 20 mg, rosuvastatin 10 mg, or TRADEMARK 10/10. After 6 weeks of treatment (Phase I), patients taking atorvastatin 20 mg who failed to achieve a LDL-C level <2.6 mmol/L were switched to either atorvastatin 40 mg or TRADEMARK 10/20 for 6 weeks (Phase II), and similar patients taking rosuvastatin 10 mg during Phase I were switched to either rosuvastatin 20 mg or TRADEMARK 10/20. Reductions in LDL-C and comparisons between the TRADEMARK group and other treatment groups studied are shown in Table 4.

<table>
<thead>
<tr>
<th>Table 4</th>
</tr>
</thead>
</table>

**Response to TRADEMARK* in High-Risk Patients with a LDL-C Level Between 2.6 and 4.1 mmol/L on Atorvastatin 10 mg Daily at Baseline**

<table>
<thead>
<tr>
<th>Treatment</th>
<th>N</th>
<th>Percent Change from Baseline †</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Total-C</td>
<td>LDL-C</td>
</tr>
<tr>
<td><strong>Phase I</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Switched from atorvastatin 10 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TRADEMARK 10/10</td>
<td>120</td>
<td>-13.5</td>
</tr>
<tr>
<td>Atorvastatin 20 mg</td>
<td>480</td>
<td>-6.4†</td>
</tr>
<tr>
<td>Rosuvastatin 10 mg</td>
<td>939</td>
<td>-7.7†</td>
</tr>
<tr>
<td><strong>Phase II</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Switched from atorvastatin 20 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TRADEMARK 10/20</td>
<td>124</td>
<td>-10.7</td>
</tr>
<tr>
<td>Atorvastatin 40 mg</td>
<td>124</td>
<td>-3.8 ‡</td>
</tr>
<tr>
<td>Switched from</td>
<td></td>
<td></td>
</tr>
<tr>
<td>rosvastatin 10 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TRADEMARK 10/20</td>
<td>231</td>
<td>-11.8</td>
</tr>
<tr>
<td>Rosuvastatin 20 mg</td>
<td>205</td>
<td>-4.5 ‡</td>
</tr>
</tbody>
</table>

* Coadministered ezetimibe and atorvastatin equivalent to TRADEMARK 10/10 or TRADEMARK 10/20
† M-Estimates (based on the method of Huber; 95% CI and p-value were obtained from fitting a robust Regression model with terms for treatment and baseline)
‡ Geometric mean percent changes from baseline in TG were calculated based on back-transformation via exponentiation of the model-based least square (LS) means and expressed as (geometric mean − 1) multiplied by 100

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>†</td>
<td>p&lt;0.001 versus TRADEMARK 10/10</td>
</tr>
<tr>
<td>‡</td>
<td>p&lt;0.01 versus TRADEMARK 10/10</td>
</tr>
<tr>
<td>‡</td>
<td>p&lt;0.05 versus TRADEMARK 10/10</td>
</tr>
<tr>
<td>‡</td>
<td>p&lt;0.001 versus TRADEMARK 10/20</td>
</tr>
</tbody>
</table>
Table 4 does not contain data comparing the effects of TRADERMARK 10/10 or 10/20 to doses higher than atorvastatin 40 mg or rosuvastatin 20 mg.

In a placebo-controlled study, the Myocardial Ischaemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study, patients with an acute coronary syndrome (non Q-wave MI or unstable angina) were randomised to receive atorvastatin 80 mg/day (n=1538) or placebo (n=1548). Treatment was initiated during the acute phase after hospital admission and lasted for 16 weeks. Atorvastatin 80 mg/day provided a 16% (p=0.048) reduction in risk of the combined primary endpoint: death from any cause, nonfatal MI, resuscitated cardiac arrest, or angina pectoris with evidence of myocardial ischaemia requiring hospitalisation. This was mainly due to a 26% reduction in re-hospitalisation for angina pectoris with evidence of myocardial ischaemia (p=0.018).

TRADEMARK contains atorvastatin. In a placebo-controlled study, the Anglo-Scandinavian Cardiac Outcomes Trial Lipid Lowering Arm (ASCOT-LLA), the effect of atorvastatin 10 mg on fatal and non-fatal CHD was assessed in 10,305 hypertensive patients, 40-80 years old, with TC levels ≤6.5 mmol/L. Patients were followed for a median duration of 3.3 years. Atorvastatin 10 mg significantly (p<0.001) reduced the relative risk for: fatal CHD plus nonfatal MI by 36% (absolute risk reduction = 1.1%); total cardiovascular events and revascularization procedures by 20% (absolute risk reduction = 1.9%); and total coronary events by 29% (absolute risk reduction = 1.4%).

In a placebo-controlled study, the Collaborative Atorvastatin Diabetes Study (CARDS), the effect of atorvastatin 10 mg on cardiovascular disease (CVD) endpoints was assessed in 2838 patients, 40-75 years old, with type 2 diabetes, one or more cardiovascular risk factors, LDL ≤4.1 mmol/L, and TG ≤6.8 mmol/L. Patients were followed for a median duration of 3.9 years. Atorvastatin 10 mg significantly (p<0.05) reduced: the rate of major cardiovascular events by 37% (absolute risk reduction = 3.2%); the risk of stroke by 48% (absolute risk reduction = 1.3%); and the risk of MI by 42% (absolute risk reduction = 1.9%).

Prevention of Cardiovascular Events

In an ezetimibe/simvastatin, multicenter, randomized, double-blind, active-control study, 18,144 patients enrolled within 10 days of hospitalization for acute coronary syndrome (ACS; either acute myocardial infarction [MI] or unstable angina [UA]). All patients were randomized in a 1:1 ratio to receive either ezetimibe/simvastatin 10/40 mg (n=9067) or simvastatin 40 mg (n=9077) and followed for a median of 6.0 years.

Patients had a mean age of 63.6 years; 76% were male, 84% were Caucasian, and 27% were diabetic. The average LDL-C value at the time of study qualifying event was 80 mg/dL (2.1 mmol/L) for those on lipid-lowering therapy (n=6390) and 101 mg/dL (2.6 mmol/L) for those not on previous lipid-lowering therapy (n=11594). Prior to the hospitalization for the qualifying ACS event, 34% of the patients were on statin therapy. At one-year, the average LDL-C for patients continuing on therapy was 53.2 mg/dL (1.4 mmol/L) for the ezetimibe/simvastatin group and 69.9 mg/dL (1.8 mmol/L) for the simvastatin monotherapy group.

The primary endpoint was a composite consisting of cardiovascular death, major coronary events (MCE; defined as non-fatal myocardial infarction, documented unstable angina that required hospitalization, or any coronary revascularization procedure occurring at least 30 days after randomized treatment assignment) and non-fatal stroke. The study demonstrated that treatment with ezetimibe/simvastatin provided incremental benefit in reducing the primary composite endpoint of cardiovascular death, MCE, and non-fatal stroke compared with simvastatin alone (relative risk reduction of 6.4%, p=0.016). The primary endpoint occurred in 2572 of 9067 patients (7-year Kaplan-Meier [KM] rate 32.72%) in the ezetimibe/simvastatin group and 2742 of 9077 patients (7-year KM rate 34.67%) in the simvastatin alone group. (See Figure 1 and Table 5.) This incremental benefit is expected to be similar with coadministration of ezetimibe and atorvastatin. Total mortality was unchanged in this high risk group.
There was an overall benefit for all strokes; however there was a small non-significant increase in hemorrhagic stroke in the ezetimibe-simvastatin group compared with simvastatin alone. The risk of hemorrhagic stroke for ezetimibe coadministered with higher potency statins in long-term outcome studies has not been evaluated.

The treatment effect of ezetimibe/simvastatin was generally consistent with the overall results across many subgroups, including sex, age, race, medical history of diabetes mellitus, baseline lipid levels, prior statin therapy, prior stroke, and hypertension.

**Figure 1: Effect of ezetimibe/simvastatin on the Primary Composite Endpoint of Cardiovascular Death, Major Coronary Event, or Non-fatal Stroke**
Table 5
Major Cardiovascular Events by Treatment Group in All Randomized Patients in IMPROVE-IT

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Ezetimibe/Simvastatin 10/40 mg* (N=9067)</th>
<th>Simvastatin 40 mg† (N=9077)</th>
<th>Hazard Ratio (95% CI)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>n</td>
<td>n K-M %‡</td>
<td>n K-M %‡</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Primary Composite Efficacy Endpoint</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(CV death, Major Coronary Events and non-fatal stroke)</td>
<td>2572 32.72%</td>
<td>2742 34.67%</td>
<td>0.936 (0.887, 0.988)</td>
<td>0.016</td>
</tr>
<tr>
<td><strong>Components of Primary Composite Endpoint and Select Efficacy Endpoints</strong></td>
<td>(first occurrences of specified event at any time)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardiovascular death</td>
<td>537 6.89%</td>
<td>538 6.84%</td>
<td>1.000 (0.887, 1.127)</td>
<td>0.997</td>
</tr>
<tr>
<td>Major Coronary Event:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-fatal MI</td>
<td>945 12.77%</td>
<td>1083 14.41%</td>
<td>0.871 (0.798, 0.950)</td>
<td>0.002</td>
</tr>
<tr>
<td>Unstable angina requiring hospitalization</td>
<td>156 2.06%</td>
<td>148 1.92%</td>
<td>1.059 (0.846, 1.326)</td>
<td>0.618</td>
</tr>
<tr>
<td>Coronary revascularization after 30 days</td>
<td>1690 21.84%</td>
<td>1793 23.36%</td>
<td>0.947 (0.886, 1.012)</td>
<td>0.107</td>
</tr>
<tr>
<td>Non-fatal stroke</td>
<td>245 3.49%</td>
<td>305 4.24%</td>
<td>0.802 (0.678, 0.949)</td>
<td>0.010</td>
</tr>
</tbody>
</table>

* 6% were uptritrated to ezetimibe/simvastatin 10/80 mg.
† 27% were uptritrated to simvastatin 80 mg.
‡ Kaplan-Meier estimate at 7 years.

**Homozygous Familial Hypercholesterolaemia (HoFH)**

A double-blind, randomised, 12-week study was performed in patients with a clinical and/or genotypic diagnosis of HoFH. Data were analyzed from a subgroup of patients (n=36) receiving atorvastatin 40 mg at baseline. Increasing the dose of atorvastatin from 40 to 80 mg (n=12) produced a reduction of LDL-C of 2% from baseline on atorvastatin 40 mg. Coadministered ezetimibe and atorvastatin equivalent to TRADEMARK (10/40 and 10/80 pooled, n=24), produced a reduction of LDL-C of 19% from baseline on atorvastatin 40 mg. In those patients coadministered ezetimibe and atorvastatin equivalent to TRADEMARK (10/80, n=12), a reduction of LDL-C of 25% from baseline on atorvastatin 40 mg was produced.

After completing the 12-week study, eligible patients (n=35), who were receiving atorvastatin 40 mg at baseline, were assigned to coadministered ezetimibe and atorvastatin equivalent to TRADEMARK 10/40 for up to an additional 24 months. Following at least 4 weeks of treatment, the atorvastatin dose could be doubled to a maximum dose of 80 mg. At the end of the 24 months, TRADEMARK (10/40 and 10/80 pooled) produced a reduction of LDL-C that was consistent with that seen in the 12-week study.

The European Medicines Agency has waived the obligation to submit the results of studies with TRADEMARK in all subsets of the paediatric population in the treatments of hypercholesterolaemia and mixed hyperlipidaemia (see section 4.2 for information on paediatric use).

**5.2 Pharmacokinetic properties**

**TRADEMARK**

TRADEMARK has been shown to be bioequivalent to coadministration of corresponding doses of ezetimibe and atorvastatin tablets.

**Absorption TRADEMARK**

The effects of a high-fat meal on the pharmacokinetics of ezetimibe and atorvastatin when administered as TRADEMARK tablets are comparable to those reported for the individual tablets.

**Ezetimibe**

After oral administration, ezetimibe is rapidly absorbed and extensively conjugated to a pharmacologically active phenolic glucuronide (ezetimibe-glucuronide). Mean maximum plasma concentrations (Cmax) occur within 1 to 2 hours for ezetimibe-glucuronide and 4 to 12 hours for
ezetimibe. The absolute bioavailability of ezetimibe cannot be determined as the compound is virtually insoluble in aqueous media suitable for injection.

Concomitant food administration (high-fat or non-fat meals) had no effect on the oral bioavailability of ezetimibe when administered as 10-mg tablets.

**Atorvastatin**
Atorvastatin is rapidly absorbed after oral administration; maximum plasma concentrations (C_{max}) occur within 1 to 2 hours. Extent of absorption increases in proportion to atorvastatin dose. After oral administration, atorvastatin film-coated tablets are 95% to 99% bioavailable compared to the oral solution. The absolute bioavailability of atorvastatin is approximately 12% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%. The low systemic availability is attributed to presystemic clearance in gastrointestinal mucosa and/or hepatic first-pass metabolism.

**Distribution**
Ezetimibe and ezetimibe-glucuronide are bound 99.7% and 88 to 92% to human plasma proteins, respectively.

**Biotransformation**
Ezetimibe
Ezetimibe is metabolised primarily in the small intestine and liver via glucuronide conjugation (a phase II reaction) with subsequent biliary excretion. Minimal oxidative metabolism (a phase I reaction) has been observed in all species evaluated. Ezetimibe and ezetimibe-glucuronide are the major drug-derived compounds detected in plasma, constituting approximately 10 to 20% and 80 to 90% of the total drug in plasma, respectively. Both ezetimibe and ezetimibe-glucuronide are slowly eliminated from plasma with evidence of significant enterohepatic recycling. The half-life for ezetimibe and ezetimibe-glucuronide is approximately 22 hours.

**Elimination**
Ezetimibe
Following oral administration of ^14^C-ezetimibe (20 mg) to human subjects, total ezetimibe accounted for approximately 93% of the total radioactivity in plasma. Approximately 78% and 11% of the administered radioactivity were recovered in the faeces and urine, respectively, over a 10-day collection period. After 48 hours, there were no detectable levels of radioactivity in the plasma.

**Atorvastatin**
Atorvastatin is metabolized by cytochrome P450 3A4 to ortho- and parahydroxylated derivatives and various beta-oxidation products. Apart from other pathways these products are further metabolized via glucuronidation. **In vitro**, inhibition of HMG-CoA reductase by ortho- and parahydroxylated metabolites is equivalent to that of atorvastatin. Approximately 70% of circulating inhibitory activity for HMG-CoA reductase is attributed to active metabolites.

**Elimination**
Ezetimibe
Atorvastatin is eliminated primarily in bile following hepatic and/or extrahepatic metabolism. However, the medicinal product does not appear to undergo significant enterohepatic recirculation. Mean plasma elimination half-life of atorvastatin in humans is approximately 14 hours. The half-life of inhibitory activity for HMG-CoA reductase is approximately 20 to 30 hours due to the contribution of active metabolites.

Atorvastatin is a substrate of the efflux transporter BCRP.
Paediatric population

**Ezetimibe**

The absorption and metabolism of ezetimibe are similar between children and adolescents (10 to 18 years) and adults. Based on total ezetimibe, there are no pharmacokinetic differences between adolescents and adults. Pharmacokinetic data in the paediatric population < 10 years of age are not available. Clinical experience in paediatric and adolescent patients (ages 9 to 17) has been limited to patients with HoFH or sitosterolaemia.

**Atorvastatin**

In an open-label, 8-week study, Tanner Stage 1 (N=15) and Tanner Stage 2 (N=24) paediatric patients (ages 6-17 years) with heterozygous familial hypercholesterolemia and baseline LDL-C ≥ 4 mmol/L were treated with 5 or 10 mg of chewable or 10 or 20 mg of film-coated atorvastatin tablets once daily, respectively. Body weight was the only significant covariate in atorvastatin population PK model. Apparent oral clearance of atorvastatin in paediatric subjects appeared similar to adults when scaled allometrically by body weight. Consistent decreases in LDL-C and TC were observed over the range of atorvastatin and o-hydroxyatorvastatin exposures.

Older people

**Ezetimibe**

Plasma concentrations for total ezetimibe are about 2-fold higher in the elderly (≥65 years) than in the young (18 to 45 years). LDL-C reduction and safety profile are comparable between elderly and younger subjects treated with ezetimibe.

**Atorvastatin**

Plasma concentrations of atorvastatin and its active metabolites are higher in healthy elderly subjects than in young adults while the lipid effects were comparable to those seen in younger patient populations.

Hepatic impairment

**Ezetimibe**

After a single 10-mg dose of ezetimibe, the mean AUC for total ezetimibe was increased approximately 1.7-fold in patients with mild hepatic insufficiency (Child-Pugh score 5 or 6), compared to healthy subjects. In a 14-day, multiple-dose study (10 mg daily) in patients with moderate hepatic insufficiency (Child-Pugh score 7 to 9), the mean AUC for total ezetimibe was increased approximately 4-fold on Day 1 and Day 14 compared to healthy subjects. No dose adjustment is necessary for patients with mild hepatic insufficiency. Due to the unknown effects of the increased exposure to ezetimibe in patients with moderate or severe (Child-Pugh score > 9) hepatic insufficiency, ezetimibe is not recommended in these patients (see sections 4.2 and 4.4).

**Atorvastatin**

Plasma concentrations of atorvastatin and its active metabolites are markedly increased (approx. 16-fold in C_{max} and approx. 11-fold in AUC) in patients with chronic alcoholic liver disease (Childs-Pugh B).

Renal impairment

**Ezetimibe**

After a single 10-mg dose of ezetimibe in patients with severe renal disease (n=8; mean CrCl ≤30 ml/min/1.73 m²), the mean AUC for total ezetimibe was increased approximately 1.5-fold, compared to healthy subjects (n=9).

An additional patient in this study (post-renal transplant and receiving multiple medicinal products, including ciclosporin) had a 12-fold greater exposure to total ezetimibe.

**Atorvastatin**

Renal disease has no influence on the plasma concentrations or lipid effects of atorvastatin and its active metabolites.
Gender

*Ezetimibe*

Plasma concentrations for total ezetimibe are slightly higher (approximately 20%) in women than in men. LDL-C reduction and safety profile are comparable between men and women treated with ezetimibe.

*Atorvastatin*

Concentrations of atorvastatin and its active metabolites in women differ from those in men (women: approx. 20% higher for C_{max} and approx. 10% lower for AUC). These differences were of no clinical significance, resulting in no clinically significant differences in lipid effects among men and women.

SLCO1B1 polymorphism

*Atorvastatin*

Hepatic uptake of all HMG-CoA reductase inhibitors, including atorvastatin, involves the OATP1B1 transporter. In patients with SLCO1B1 polymorphism there is a risk of increased exposure of atorvastatin, which may lead to an increased risk of rhabdomyolysis (see section 4.4). Polymorphism in the gene encoding OATP1B1 (SLCO1B1 c.521CC) is associated with a 2.4-fold higher atorvastatin exposure (AUC) than in individuals without this genotype variant (c.521TT). A genetically impaired hepatic uptake of atorvastatin is also possible in these patients. Possible consequences for the efficacy are unknown.

5.3 Preclinical safety data

*TRADEMARK*

In three-month coadministration studies in rats and dogs with ezetimibe and atorvastatin, the toxic effects observed were essentially those typically associated with statins. The statin-like histopathologic findings were limited to the liver. Some of the toxic effects were more pronounced than those observed during treatment with statins alone. This is attributed to pharmacokinetic and/or pharmacodynamic interactions following coadministration.

The coadministration of ezetimibe and atorvastatin in pregnant rats indicated that there was a test article-related increase in the skeletal variation “reduced ossification of the sternebrae” in the high dose (1000/108.6 mg/kg) ezetimibe/atorvastatin group. This may be related to the observed decrease in foetal body weights. In pregnant rabbits a low incidence of skeletal deformities (fused sternebrae, fused caudal vertebrae and asymmetrical sternebrae variation) were observed.

In a series of *in vivo* and *in vitro* assays, ezetimibe, given alone or coadministered with atorvastatin, exhibited no genotoxic potential.

Ezetimibe

Animal studies on the chronic toxicity of ezetimibe identified no target organs for toxic effects. In dogs treated for four weeks with ezetimibe (≥0.03 mg/kg/day) the cholesterol concentration in the cystic bile was increased by a factor of 2.5 to 3.5. However, in a one-year study on dogs given doses of up to 300 mg/kg/day no increased incidence of cholelithiasis or other hepatobiliary effects were observed. The significance of these data for humans is not known. A lithogenic risk associated with the therapeutic use of ezetimibe cannot be ruled out.

Long-term carcinogenicity tests on ezetimibe were negative.

Ezetimibe had no effect on the fertility of male or female rats, nor was it found to be teratogenic in rats or rabbits, nor did it affect prenatal or postnatal development. Ezetimibe crossed the placental barrier in pregnant rats and rabbits given multiple doses of 1000 mg/kg/day.

Atorvastatin

Atorvastatin was negative for mutagenic and clastogenic potential in a battery of 4 *in vitro* tests and 1 *in vivo* assay. Atorvastatin was not found to be carcinogenic in rats, but high doses in mice (resulting in 6-11 fold the AUC0-24h reached in humans at the highest recommended dose) showed
hepatocellular adenomas in males and hepatocellular carcinomas in females. There is evidence from animal experimental studies that HMG-CoA reductase inhibitors may affect the development of embryos or fetuses. In rats, rabbits, and dogs atorvastatin had no effect on fertility and was not teratogenic; however, at maternally toxic doses foetal toxicity was observed in rats and rabbits. The development of the rat offspring was delayed and post-natal survival reduced during exposure of the dams to high doses of atorvastatin. In rats, there is evidence of placental transfer. In rats, plasma concentrations of atorvastatin are similar to those in milk. It is not known whether atorvastatin or its metabolites are excreted in human milk.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Tablet core
Ezetimibe Layer
Croscarmellose sodium
Lactose monohydrate
Magnesium stearate
Cellulose, microcrystalline
Povidone
Sodium laurilsulfate

Atorvastatin Layer
Cellulose, microcrystalline
Lactose monohydrate
Hydroxypropylcellulose
Croscarmellose sodium
Polysorbate 80
Calcium carbonate
Magnesium stearate
Silica, colloidal anhydrous

Film coating
Hypermellose
Macrogol 8000
Titanium dioxide (E171)
Talc

6.2 Incompatibilities

Not applicable.

6.3 Shelf-life

2 years

6.4 Special precautions for storage

Store in the original package in order to protect from oxygen.

6.5 Nature and contents of container

TRADEMARK 10 mg/10 mg, 10 mg/20 mg, 10 mg/40 mg, and 10 mg/80 mg
Packs of 10, 30, 90, and 100 film-coated tablets in nitrogen-purged aluminium/aluminium (oPA-Al-PVC cavity with Al lidding) blisters.
Packs of 30 x 1 and 45 x 1 film-coated tablets in unit dose nitrogen-purged aluminium/aluminium (oPA-Al-PVC cavity with Al lidding) blisters.

Not all pack sizes may be marketed.

6.6 Special precautions for disposal

No special requirements.

7. MARKETING AUTHORISATION HOLDER

Merck Sharp & Dohme Ltd
Hertford Road, Hoddesdon
Hertfordshire EN11 9BU
United Kingdom

8. MARKETING AUTHORISATION NUMBER(S)

To be completed nationally.

9. DATE OF FIRST AUTHORISATION/RENEWAL OF AUTHORISATION

To be completed nationally.

10. DATE OF REVISION OF THE TEXT

To be completed nationally.
LABELLING
PARTICULARS TO APPEAR ON THE OUTER PACKAGING

Outer carton for TRADEMARK 10 mg/10 mg film-coated tablets

1. NAME OF THE MEDICINAL PRODUCT

TRADEMARK 10 mg/10 mg film-coated tablets
ezetimibe/atorvastatin

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each film-coated tablet contains 10 mg ezetimibe and 10 mg of atorvastatin (as atorvastatin calcium trihydrate).

3. LIST OF EXCIPIENTS

Contains lactose.
See package leaflet for further information.

4. PHARMACEUTICAL FORM AND CONTENTS

Film-coated tablets
10 film-coated tablets
30 film-coated tablets
90 film-coated tablets
100 film-coated tablets
30x1 film-coated tablets
45x1 film-coated tablets

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Oral use. Read the package leaflet before use.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP
9. SPECIAL STORAGE CONDITIONS

Store in the original package in order to protect from oxygen.

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Merck Sharp & Dohme Ltd
Hertford Road, Hoddesdon
Hertfordshire EN11 9BU
United Kingdom

12. MARKETING AUTHORISATION NUMBER(S)

[assigned MA number] 10 film-coated tablets
[assigned MA number] 30 film-coated tablets
[assigned MA number] 90 film-coated tablets
[assigned MA number] 100 film-coated tablets
[assigned MA number] 30x1 film-coated tablets
[assigned MA number] 45x1 film-coated tablets

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

To be completed nationally

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

TRADEMARK 10 mg/10 mg film-coated tablets
PARTICULARS TO APPEAR ON THE OUTER PACKAGING

Outer carton for TRADEMARK 10 mg/20 mg film-coated tablets

1. NAME OF THE MEDICINAL PRODUCT

TRADEMARK 10 mg/20 mg film-coated tablets ezetimibe/atorvastatin

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each film-coated tablet contains 10 mg ezetimibe and 20 mg of atorvastatin (as atorvastatin calcium trihydrate).

3. LIST OF EXCIPIENTS

Contains lactose.
See package leaflet for further information.

4. PHARMACEUTICAL FORM AND CONTENTS

Film-coated tablets
10 film-coated tablets
30 film-coated tablets
90 film-coated tablets
100 film-coated tablets
30x1 film-coated tablets
45x1 film-coated tablets

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Oral use. Read the package leaflet before use.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP
9. SPECIAL STORAGE CONDITIONS

Store in the original package in order to protect from oxygen.

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Merck Sharp & Dohme Ltd
Hertford Road, Hoddesdon
Hertfordshire EN11 9BU
United Kingdom

12. MARKETING AUTHORISATION NUMBER(S)

[assigned MA number] 10 film-coated tablets
[assigned MA number] 30 film-coated tablets
[assigned MA number] 90 film-coated tablets
[assigned MA number] 100 film-coated tablets
[assigned MA number] 30x1 film-coated tablets
[assigned MA number] 45x1 film-coated tablets

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

To be completed nationally

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

TRADEMARK 10 mg/20 mg film-coated tablets
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
Outer carton for TRADEMARK 10 mg/40 mg film-coated tablets

1. NAME OF THE MEDICINAL PRODUCT

TRADEMARK 10 mg/40 mg film-coated tablets
ezetimibe/atorvastatin

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each film-coated tablet contains 10 mg ezetimibe and 40 mg of atorvastatin (as atorvastatin calcium trihydrate).

3. LIST OF EXCIPIENTS

Contains lactose.
See package leaflet for further information.

4. PHARMACEUTICAL FORM AND CONTENTS

Film-coated tablets

10 film-coated tablets
30 film-coated tablets
90 film-coated tablets
100 film-coated tablets
30x1 film-coated tablets
45x1 film-coated tablets

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Oral use. Read the package leaflet before use.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP
9. **SPECIAL STORAGE CONDITIONS**

    Store in the original package in order to protect from oxygen.

10. **SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**

11. **NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

    Merck Sharp & Dohme Ltd
    Hertford Road, Hoddesdon
    Hertfordshire EN11 9BU
    United Kingdom

12. **MARKETING AUTHORISATION NUMBER(S)**

    [assigned MA number] 10 film-coated tablets
    [assigned MA number] 30 film-coated tablets
    [assigned MA number] 90 film-coated tablets
    [assigned MA number] 100 film-coated tablets
    [assigned MA number] 30x1 film-coated tablets
    [assigned MA number] 45x1 film-coated tablets

13. **BATCH NUMBER**

    Lot

14. **GENERAL CLASSIFICATION FOR SUPPLY**

    To be completed nationally

15. **INSTRUCTIONS ON USE**

16. **INFORMATION IN BRAILLE**

    TRADEMARK 10 mg/40 mg film-coated tablets
PARTICULARS TO APPEAR ON THE OUTER PACKAGING

Outer carton for TRADEMARK 10 mg/80 mg film-coated tablets

1.  NAME OF THE MEDICINAL PRODUCT

TRADEMARK 10 mg/80 mg film-coated tablets
ezetimibe/atorvastatin

2.  STATEMENT OF ACTIVE SUBSTANCE(S)

Each film-coated tablet contains 10 mg ezetimibe and 80 mg of atorvastatin (as atorvastatin calcium trihydrate).

3.  LIST OF EXCIPIENTS

Contains lactose.
See package leaflet for further information.

4.  PHARMACEUTICAL FORM AND CONTENTS

Film-coated tablets

10 film-coated tablets
30 film-coated tablets
90 film-coated tablets
100 film-coated tablets
30x1 film-coated tablets
45x1 film-coated tablets

5.  METHOD AND ROUTE(S) OF ADMINISTRATION

Oral use. Read the package leaflet before use.

6.  SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7.  OTHER SPECIAL WARNING(S), IF NECESSARY

8.  EXPIRY DATE

EXP
9. **SPECIAL STORAGE CONDITIONS**

Store in the original package in order to protect from oxygen.

10. **SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**

11. **NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Merck Sharp & Dohme Ltd
Hertford Road, Hoddesdon
Hertfordshire EN11 9BU
United Kingdom

12. **MARKETING AUTHORISATION NUMBER(S)**

[assigned MA number] 10 film-coated tablets
[assigned MA number] 30 film-coated tablets
[assigned MA number] 90 film-coated tablets
[assigned MA number] 100 film-coated tablets
[assigned MA number] 30x1 film-coated tablets
[assigned MA number] 45x1 film-coated tablets

13. **BATCH NUMBER**

Lot

14. **GENERAL CLASSIFICATION FOR SUPPLY**

To be completed nationally

15. **INSTRUCTIONS ON USE**

16. **INFORMATION IN BRAILLE**

TRADEMARK 10 mg/80 mg film-coated tablets
### MINIMUM PARTICULARS TO APPEAR ON BLISTERS

Blister for TRADEMARK 10 mg/10 mg, 10 mg/20 mg, 10 mg/40 mg, 10 mg/80 mg film-coated tablets – Individual packs

<table>
<thead>
<tr>
<th>1. NAME OF THE MEDICINAL PRODUCT</th>
</tr>
</thead>
<tbody>
<tr>
<td>TRADEMARK 10 mg/10 mg film-coated tablets</td>
</tr>
<tr>
<td>TRADEMARK 10 mg/20 mg film-coated tablets</td>
</tr>
<tr>
<td>TRADEMARK 10 mg/40 mg film-coated tablets</td>
</tr>
<tr>
<td>TRADEMARK 10 mg/80 mg film-coated tablets</td>
</tr>
<tr>
<td>ezetimibe/atorvastatin</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2. NAME OF THE MARKETING AUTHORISATION HOLDER</th>
</tr>
</thead>
<tbody>
<tr>
<td>MSD</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>3. EXPIRY DATE</th>
</tr>
</thead>
<tbody>
<tr>
<td>EXP</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>4. BATCH NUMBER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lot</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>5. OTHER</th>
</tr>
</thead>
</table>
PACKAGE LEAFLET
Package leaflet: Information for the user

TRADEMARK 10 mg/10 mg film-coated tablets
TRADEMARK 10 mg/20 mg film-coated tablets
TRADEMARK 10 mg/40 mg film-coated tablets
TRADEMARK 10 mg/80 mg film-coated tablets

ezetimibe and atorvastatin

Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor or pharmacist.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet
1. What TRADEMARK is and what it is used for
2. What you need to know before you take TRADEMARK
3. How to take TRADEMARK
4. Possible side effects
5. How to store TRADEMARK
6. Contents of the pack and other information

1. What TRADEMARK is and what it is used for

TRADEMARK is a medicine to lower increased levels of cholesterol. TRADEMARK contains ezetimibe and atorvastatin.

TRADEMARK is used in adults to lower levels of total cholesterol, “bad” cholesterol (LDL cholesterol), and fatty substances called triglycerides in the blood. In addition, TRADEMARK raises levels of “good” cholesterol (HDL cholesterol).

TRADEMARK works to reduce your cholesterol in two ways. It reduces the cholesterol absorbed in your digestive tract, as well as the cholesterol your body makes by itself.

Cholesterol is one of several fatty substances found in the bloodstream. Your total cholesterol is made up mainly of LDL and HDL cholesterol.

LDL cholesterol is often called “bad” cholesterol because it can build up in the walls of your arteries forming plaque. Eventually, this plaque build-up can lead to a narrowing of the arteries. This narrowing can slow or block blood flow to vital organs such as the heart and brain. This blocking of blood flow can result in a heart attack or stroke.

HDL cholesterol is often called “good” cholesterol because it helps keep the bad cholesterol from building up in the arteries and protects against heart disease.

Triglycerides are another form of fat in your blood that may increase your risk for heart disease.

TRADEMARK is used for patients who cannot control their cholesterol levels by diet alone. You should stay on a cholesterol-lowering diet while taking this medicine.

TRADEMARK is used in addition to your cholesterol-lowering diet if you have:
- a raised cholesterol level in your blood (primary hypercholesterolaemia [heterozygous familial and non-familial]) or elevated fat levels in your blood (mixed hyperlipidaemia)
  - that is not well controlled with a statin alone;
  - for which you have used a statin and ezetimibe as separate tablets.
- a hereditary illness (homozygous familial hypercholesterolaemia) that increases the cholesterol level in your blood. You may also receive other treatments.
- heart disease. TRADEMARK reduces the risk of heart attack, stroke, surgery to increase heart blood flow, or hospitalization for chest pain.

TRADEMARK does not help you lose weight.

2. **What you need to know before you take TRADEMARK**

**Do not take TRADEMARK if**
- you are allergic to ezetimibe, atorvastatin or any of the other ingredients of this medicine (listed in section 6)
- you have or have ever had a disease that affects the liver
- you have had any unexplained abnormal blood tests for liver function
- you are a woman able to have children and are not using reliable contraception
- you are pregnant, trying to become pregnant or are breast-feeding

**Warnings and precautions**

Talk to your doctor or pharmacist before taking TRADEMARK if
- you have had a previous stroke with bleeding into the brain, or have small pockets of fluid in the brain from previous strokes
- you have kidney problems
- you have an under-active thyroid gland (hypothyroidism)
- you have had repeated or unexplained muscle aches or pains, a personal history or family history of muscle problems
- you have had previous muscular problems during treatment with other lipid-lowering medicines (e.g. other “statin” or “fibrate” medicines)
- you regularly drink a large amount of alcohol
- you have a history of liver disease
- you are older than 70 years
- you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this product
- you are taking or have taken in the last 7 days a medicine called fusidic acid, (a medicine for bacterial infection) orally or by injection. The combination of fusidic acid and TRADEMARK can lead to serious muscle problems (rhabdomyolysis)

Contact your doctor promptly if you experience unexplained muscle pain, tenderness, or weakness while taking TRADEMARK. This is because on rare occasions, muscle problems can be serious, including muscle breakdown resulting in kidney damage. Atorvastatin is known to cause muscle problems, and cases of muscle problems have also been reported with ezetimibe.

Also tell your doctor or pharmacist if you have a muscle weakness that is constant. Additional tests and medicines may be needed to diagnose and treat this.

Check with your doctor or pharmacist before taking TRADEMARK – if you have severe respiratory failure.

If any of these apply to you (or you are not sure), talk to your doctor or pharmacist before taking TRADEMARK because your doctor will need to carry out a blood test before and possibly during
your TRADEMARK treatment to predict your risk of muscle-related side effects. The risk of muscle-
related side effects, e.g. rhabdomyolysis, is known to increase when certain medicines are taken at the
same time (see section 2 “Other medicines and TRADEMARK”).

While you are on this medicine your doctor will monitor you closely if you have diabetes or are at risk
of developing diabetes. You are likely to be at risk of developing diabetes if you have high levels of
sugars and fats in your blood, are overweight and have high blood pressure.

Tell your doctor about all your medical conditions including allergies.

The combined use of TRADEMARK and fibrates (medicines for lowering cholesterol) should be
avoided since the combined use of TRADEMARK and fibrates has not been studied.

**Children**

TRADEMARK is not recommended for children and adolescents.

**Other medicines and TRADEMARK**

Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other
medicines, including those obtained without prescription.

There are some medicines that may change the effect of TRADEMARK or their effect may be
changed by TRADEMARK (see section 3). This type of interaction could make one or both of the
medicines less effective. Alternatively it could increase the risk or severity of side effects, including
the important muscle wasting condition known as “rhabdomyolysis” described in section 4:

- ciclosporin (a medicine often used in organ transplant patients)
- erythromycin, clarithromycin, telithromycin, fusidic acid**, rifampicin (medicines for bacterial
  infections)
- ketoconazole, itraconazole, voriconazole, fluconazole, posaconazole (medicines for fungal
  infections)
- gemfibrozil, other fibrates, nicotinic acid, derivatives, colestipol, colestyramine (medicines for
  regulating lipid levels)
- some calcium channel blockers used for angina or high blood pressure, e.g., amlodipine,
  diltiazem
- digoxin, verapamil, amiodarone (medicines to regulate your heart rhythm)
- medicines used in the treatment of HIV, e.g., ritonavir, lopinavir, atazanavir, indinavir,
  darunavir, the combination of tipranavir/ritonavir, etc. (medicines for AIDS)
- some medicines used in the treatment of hepatitis C, e.g., telaprevir

**If you need to take oral fusidic acid to treat a bacterial infection you will need to
temporarily stop using this medicine. Your doctor will tell you when it is safe to restart
TRADEMARK. Taking TRADEMARK with fusidic acid may rarely lead to muscle
weakness, tenderness or pain (rhabdomyolysis). See more information regarding
rhabdomyolysis in section 4.

- Other medicines known to interact with TRADEMARK
  - oral contraceptives (medicines for preventing pregnancy)
  - stiripentol (an anticonvulsant medicine for epilepsy)
  - cimetidine (a medicine used for heartburn and peptic ulcers)
  - phenazone (a painkiller)
  - antacids (indigestion products containing aluminium or magnesium)
  - warfarin, phenprocoumon, acenocoumarol or fluindione (medicines to prevent blood
    clots)
  - Hepatitis C antiviral agents such as boceprevir, elbasvir, or grazoprevir (medicines used
to fight against hepatitis C infection)
  - colchicine (used to treat gout)
  - St John's Wort (a medicine to treat depression)
TRADEMARK with food and alcohol
See section 3 for instructions on how to take TRADEMARK. Please note the following:

Grapefruit juice
Do not take more than one or two small glasses of grapefruit juice per day because large quantities of grapefruit juice can change the effects of TRADEMARK.

Alcohol
Avoid drinking too much alcohol while taking this medicine. See Section 2 “Warnings and precautions” for details.

Pregnancy and breast-feeding
Do not take TRADEMARK if you are pregnant, are trying to get pregnant or think you may be pregnant. Do not take TRADEMARK if you are able to become pregnant unless you use reliable contraceptive measures. If you get pregnant while taking TRADEMARK, stop taking it immediately and tell your doctor.

Do not take TRADEMARK if you are breast-feeding.

The safety of TRADEMARK during pregnancy and breast-feeding has not yet been proven.

Ask your doctor or pharmacist for advice before taking this medicine.

Driving and using machines
TRADEMARK is not expected to interfere with your ability to drive or to use machinery. However, it should be taken into account that some people may get dizzy after taking TRADEMARK.

TRADEMARK contains lactose
TRADEMARK tablets contain a sugar called lactose. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.

3. How to take TRADEMARK

Always take this medicine exactly as your doctor has told you. Your doctor will determine the appropriate tablet strength for you, depending on your current treatment and your personal risk status. Check with your doctor or pharmacist if you are not sure.

- Before starting TRADEMARK, you should be on a diet to lower your cholesterol.
- You should keep on this cholesterol-lowering diet while taking TRADEMARK.

How much to take
The recommended dose is one TRADEMARK tablet by mouth once a day.

When to take
Take TRADEMARK at any time of the day. You can take it with or without food.

If your doctor has prescribed TRADEMARK along with colestyramine or any other bile acid sequestrant (medicines for lowering cholesterol), you should take TRADEMARK at least 2 hours before or 4 hours after taking the bile acid sequestrant.

If you take more TRADEMARK than you should
Please contact your doctor or pharmacist.

If you forget to take TRADEMARK
Do not take an extra dose; just take your normal amount of TRADEMARK at the usual time the next day.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

4. Possible side effects

Like all medicines, TRADEMARK can cause side effects, although not everybody gets them.

If you experience any of the following serious side effects, stop taking your tablets and tell your doctor immediately or go to the nearest hospital accident and emergency department.

- serious allergic reaction which causes swelling of the face, tongue and throat that can cause great difficulty in breathing
- serious illness with severe peeling and swelling of the skin, blistering of the skin, mouth, eyes, genitals and fever; skin rash with pink-red blotches especially on palms of hands or soles of feet, which may blister
- muscle weakness, tenderness or pain and particularly, if at the same time, you feel unwell or have a high temperature it may be caused by an abnormal muscle breakdown which can be life-threatening and lead to kidney problems

You should consult your doctor as soon as possible if you experience problems with unexpected or unusual bleeding or bruising, because this may be suggestive of a liver complaint.

The following common side effects were reported (may affect up to 1 in 10 people):
- diarrhoea
- muscle aches

The following uncommon side effects were reported (may affect up to 1 in 100 people):
- the flu
- depression; trouble sleeping; sleep disorder
- dizziness; headache; tingling sensation
- slow heart beat
- hot flush
- shortness of breath
- abdominal pain; abdominal bloating; constipation; indigestion; flatulence; frequent bowel movements; inflammation of the stomach; nausea; stomach discomfort; upset stomach
- acne; hives
- joint pain; back pain; leg cramps; muscle fatigue, spasms, or weakness; pain in arms and legs
- unusual weakness; feeling tired or unwell; swelling especially in the ankles (oedema)
- elevations in some laboratory blood tests of liver or muscle (CK) function
- weight gain

Additionally, the following side effects have been reported in people taking TRADEMARK, or ezetimibe or atorvastatin tablets:
- allergic reactions including swelling of the face, lips, tongue, and/or throat that may cause difficulty in breathing or swallowing (which requires treatment immediately)
- raised red rash, sometimes with target-shaped lesions
- liver problems
- cough
- heartburn
- decreased appetite; loss of appetite
- high blood pressure
- skin rash and itching; allergic reactions including rash and hives
- tendon injury
- gallstones or inflammation of the gallbladder (which may cause abdominal pain, nausea, vomiting)
- inflammation of the pancreas often with severe abdominal pain
- reduction in blood cell counts, which may cause bruising/bleeding (thrombocytopenia)
- inflammation of the nasal passages; nose bleed
- neck pain; pain; chest pain; pain in the throat
- increases and decreases in blood sugar levels (if you have diabetes you should continue careful monitoring of your blood sugar levels)
- having nightmares
- numbness or tingling in the fingers and toes
- reduction of sensation to pain or touch
- change in sense of taste; dry mouth
- loss of memory
- ringing in the ears and/or head; hearing loss
- vomiting
- belching
- hair loss
- raised temperature
- urine tests that are positive for white blood cells
- blurred vision; visual disturbances
- gynecomastia (breast enlargement in men).

Possible side effects reported with some statins
- sexual difficulties
- depression
- breathing problems including persistent cough and/or shortness of breath or fever
- diabetes. This is more likely if you have high levels of sugars and fats in your blood, are overweight and have high blood pressure. Your doctor will monitor you while you are taking this medicine.
- muscle pain, tenderness, or weakness that is constant and particularly if, at the same time, you feel unwell or have a high temperature that may not go away after stopping TRADEMARK (frequency not known).

**Reporting of side effects**
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.

5. **How to store TRADEMARK**
- Keep this medicine out of the sight and reach of children.
- Do not take TRADEMARK after the expiry date stated on the carton or container after “EXP.” The expiry date refers to the last day of that month.
- Store in the original package in order to protect from oxygen.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.

6. **Contents of the pack and other information**

What TRADEMARK contains
The active substances are ezetimibe and atorvastatin. Each film-coated tablet contains 10 mg ezetimibe and 10 mg, 20 mg, 40 mg, or 80 mg atorvastatin (as atorvastatin calcium trihydrate).

The other ingredients are: calcium carbonate; silica, colloidal anhydrous; croscarmellose sodium; hydroxypropylcellulose; lactose monohydrate; magnesium stearate; cellulose, microcrystalline; polysorbate 80; povidone; sodium laurylsulfate.

The film coating contains: hypromellose, macrogol 8000, titanium dioxide (E171), talc.

**What TRADEMARK looks like and contents of the pack**

Capsule-shaped, biconvex, film-coated tablets, white to off white.

TRADEMARK 10 mg/10 mg tablets: “257” debossed on one side
TRADEMARK 10 mg/20 mg tablets: “333” debossed on one side
TRADEMARK 10 mg/40 mg tablets: “337” debossed on one side
TRADEMARK 10 mg/80 mg tablets: “357” debossed on one side

**Pack sizes:**
Packs of 10, 30, 90, and 100 film-coated tablets in nitrogen-purged aluminium/aluminium (oPA-Al-PVC cavity with Al lidding) blisters.

Packs of 30 x 1 and 45 x 1 film-coated tablets in unit dose, nitrogen-purged aluminium/aluminium (oPA-Al-PVC cavity with Al lidding) blisters.

Not all pack sizes may be marketed.

**Marketing Authorisation Holder and Manufacturer**

Marketing Authorisation Holder
Merck Sharp & Dohme Ltd
Hertford Road, Hoddesdon
Hertfordshire EN11 9BU
United Kingdom

Manufacturer
Merck Sharp & Dohme B.V.
Waarderweg 39
2031 BN Haarlem,
The Netherlands

This medicinal product is authorised in the Member States of the EEA under the following names:

DE/H/3895/001-004/DC
Austria, Belgium, Bulgaria, Croatia, Denmark, Germany, Iceland, Ireland, Italy, Luxembourg, Malta, The Netherlands, Norway, Poland, Portugal, Romania, Slovak Republic, Slovenia, Spain, Sweden, United Kingdom

Cyprus, France, Greece, Hungary – LIPTRUZET
Czech Republic – ZOLETORV

DE/H/3896/001-004/DC
Germany, Greece, Italy, Spain – KEXROLT
France – SERSEMIC
DE/H/3897/001-004/DC
Czech Republic, Germany, Greece, Italy, Portugal, Slovak Republic, Spain

Czech Republic, Germany, Greece, Italy, Portugal, Slovak Republic, Spain

DE/H/3898/001-004/DC
Germany – TIOBLIS
Austria – EZETIMIB/ATORVASTATIN MSD
Spain – ZARDIUX

This leaflet was last revised in {MM/YYYY}
<[To be completed nationally]>